ResMed Inc. vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? ResMed Inc. trades at $230.05 (market cap $31.89B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $213.76 (market cap $39.15B). The key difference: TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is the larger of the two by market cap, and ResMed Inc. pays a 1.16% dividend while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock for 111 Days on average.
| RMD | TTWO | |
|---|---|---|
Market Cap | $31.89B | $39.15B |
Volume | 618,314 | 2,708,429 |
Sector | Health | Technology |
52-Week High | $277.88 | $262.29 |
52-Week Low | $182.82 | $189.69 |
Typical Hold Time | 51 Days | 111 Days |
Enterprise Value | $31.24B | $40.27B |
Dividend Yield | 1.16% | — |
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $230.05, up 1.8% on the day, with a bullish technical outlook and strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $2.95 exceeding the $2.89 estimate. Revenue growth is robust, reaching $5.15 billion in 2025, while profitability metrics like a 26.94% net income margin and 24.27% ROE highlight operational efficiency. Recent news includes an upcoming Q1 2027 earnings report and positive analyst commentary on growth prospects driven by demand in sleep therapy.
The investment outlook is positive, supported by earnings momentum, a consensus price target of $242.70, and institutional buying. Key risks include competitive pressures, regulatory investigations, and macroeconomic volatility. The stock offers upside potential but requires monitoring of execution and external challenges.
Take-Two Interactive (TTWO) trades at $213.44, up 4.62% today, showing strong momentum ahead of GTA VI's November launch. The stock maintains a bullish technical signal with support at $206 and resistance at $215. Despite recent earnings volatility with a Q2 miss, analyst consensus remains overwhelmingly positive with 79% buy ratings and a $292.30 price target, representing 37% upside potential from current levels.
While TTWO faces fundamental challenges with negative net margins and elevated debt levels, the imminent GTA VI release provides significant catalyst potential. Investors should weigh the substantial growth opportunity against execution risks and current valuation metrics that price in successful game performance. The stock's trajectory will likely hinge on GTA VI's commercial success and the company's ability to return to profitability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →